elezanumab   Click here for help

GtoPdb Ligand ID: 9290

Synonyms: ABT-555 | AE12-1Y-QL
Immunopharmacology Ligand
Compound class: Antibody
Comment: Elezanumab (ABT-555) is a fully human monoclonal antibody targeting repulsive guidance molecule-a (RGMA), in development as a potential therapy for multiple sclerosis (MS).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2013112922 [2].
No information available.
Summary of Clinical Use Click here for help
Elezanumab (ABT-555) is being evaluated in Phase 1 clinical trial in patients with relapsing forms of MS (see NCT02601885).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibition of RGMA is expected to promote regeneration and neuroprotection in MS [1], acting to concurrently block autoimmune demyelination and axon injury.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02601885 A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis Phase 1 Interventional AbbVie